HomeNewsGlobal Pharma

Trevi Therapeutics Welcomes James V. Cassella as Chief Development Officer

Trevi Therapeutics Welcomes James V. Cassella as Chief Development Officer

Trevi Therapeutics, Inc. has appointed James V. Cassella, PhD, as Chief Development Officer (CDO). 

"I am delighted to welcome Jim, who has been a member of our Board of Directors for the past four years, to our executive management team as Chief Development Officer," said Jennifer Good, President and CEO of Trevi Therapeutics.

"Our team is planning for the pivotal development program in IPF, the advancement in refractory chronic cough, and preparing for regulatory submission of Haduvio.

Jim will play an integral role in progressing Haduvio by utilizing his broad drug development experience and his proven hands-on leadership of scientific and regulatory teams through drug approvals.

In particular, his extensive experience and execution in central nervous system (CNS) drug development together with his long-standing knowledge of Haduvio as a member of our board of directors, positions him to make an immediate impact at this important time for the company," said Good.

"I am very excited to join the team at Trevi in a direct leadership role as I see the great potential that Haduvio's central and peripheral mechanism could have on treating patients suffering from chronic cough conditions," said Dr. Cassella.

"It is a very important time at Trevi with the upcoming data read-outs and I look forward to leveraging my late-stage CNS drug development and regulatory experience to advance Haduvio through to approval," Dr. Cassella added.

Dr. Cassella has over 35 years of experience working in innovative publicly traded drug and product development companies with a specific focus on CNS therapies. Prior to joining Trevi as CDO, Dr. Cassella served as CDO for Concert Pharmaceuticals, where he spearheaded the development activities leading to the successful US FDA approval of the autoimmune JAK inhibitor, Leqselvi.

At Concert Pharmaceuticals, he was a key member of the Executive Team and the corporate transaction team leading to its USD 576 million Company acquisition by Sun Pharmaceutical Industries. Prior to joining Concert, Dr. Cassella was Executive Vice President, Research and Development and Chief Scientific Officer at Alexza Pharmaceuticals from 2004-2015, where he was responsible for the US and European approval of the CNS drug, Adasuve.  

He held other various management positions, including Senior Vice President of Clinical Research and Development at Neurogen Corporation, an innovative CNS-focused biotechnology company, and was an Assistant Professor of Neuroscience at Oberlin College. Dr. Cassella received a PhD in Physiological Psychology from Dartmouth College, completed a postdoctoral fellowship in the Department of Psychiatry at the Yale School of Medicine and received a BA in Psychology from the University of New Haven.

Dr. Cassella will replace Dr. David Clark, who has stepped down as Chief Medical Officer to help with the care of an immediate family member but will continue to consult for the company.

"We want to thank David for his contributions at Trevi and wish him and his family the best," said Good.

More news about: global pharma | Published by Aishwarya | October - 01 - 2024 | 155

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members